← Back to Search

Radioactive Agent

Gallium Dotatate for Pancreatic Neuroendocrine Tumors

Phase < 1
Waitlist Available
Led By Sushanth Reddy, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline through 12 months
Awards & highlights

Summary

This trial uses a special scan to help doctors see and remove hard-to-find Neuroendocrine tumors more effectively. The scan uses a tracer that lights up the tumors, making them easier to locate during surgery. This approach aims to improve outcomes for patients with these types of tumors.

Eligible Conditions
  • Pancreatic Neuroendocrine Tumors
  • Carcinoid Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline through 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline through 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comparison of intraoperative findings to preoperative PET scan findings
Secondary study objectives
Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement

Trial Design

1Treatment groups
Experimental Treatment
Group I: Gallium DotatateExperimental Treatment1 Intervention
All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,621 Previous Clinical Trials
2,290,978 Total Patients Enrolled
Sushanth Reddy, MDPrincipal Investigator - University of Alabama at Birmingham
Birmingham VA Medical Center
University Of Alabama School Of Medicine (Medical School)
University Of Ky A B Chandler (Residency)
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top